Hikma Pharmaceuticals Regulatory News (HIK)

11 Sep 2007 16:28

Hikma Pharmaceuticals Plc11 September 2007 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 11 September 2007: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following awards underthe Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP") toDirectors/Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards were made on 10 September 2007 at a price of £4.1225 per ordinary shareas follows:- Name of PDMR Number of Shares awarded under the LTIP Said Darwazah 100,000 Mazen Darwazah 50,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS - Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange